FDA Approves Krystal Biotech’s VYJUVEK™: First Redosable Skin-disorder Gene Therapy
Krystal Biotech, Inc., a Pennsylvania-headquartered biotech company specialising in genetic medicines for rare diseases, announced on Friday that the US
Read moreKrystal Biotech, Inc., a Pennsylvania-headquartered biotech company specialising in genetic medicines for rare diseases, announced on Friday that the US
Read moreReCode Therapeutics, announced the dosing of the first participants in a Phase 1 trial designed to evaluate the safety and
Read morePfizer Inc. (NYSE: PFE) announced in late December, positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene
Read moreTezepelumab, developed by AstraZeneca in collaboration with Amgen, has been granted Orphan Drug Designation (ODD) in the US FDA for
Read moreTakeda and JCR Pharmaceuticals announced today a geo-based exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafusp alfa), an
Read moreSanofi announced that it will purchase U.S. biotech Kadmon to enhance its transplant business for approximately $1.9 billion. Sanofi and
Read moreEli Lilly & Co and Prevail Therapeutics announced a definitive agreement for Lilly to acquire Prevail for a total consideration
Read more